On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine. A fourth product, RHA 1, is currently in clinical trials in the US with FDA approval anticipated in 2021. Almirall seeks to enhance its early-stage research portfolio and expand its medical dermatology pipeline with three new collaborations.
New treatments and medical controversies take center stage at Cosmetic Surgery Forum as the meeting moves to Nashville in its 11th Year. Leo Pharma’s tralokinumab meets all primary and secondary endpoints in three pivotal Phase 3 studies for the treatment of adults with moderate-to-severe atopic dermatitis.
News | October 18, 2019
New data for Eli Lilly and Company’s Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab have been presented at the 28th annual European Academy of Dermatology and Venereology (EADV)...
In this week’s edition: Galderma’s Aklief (trifarotene) topical cream is now approved for acne. Sandra Johnson, MD weighs in. Supported by Sanofi and Regeneron in partnership with the National Eczema Association, the Understand AD Squad includes dermatologist Mercedes Gonzalez, MD, who discusses her experience. Sandy Klein, co-trustee of the Lynn Waxman Foundation, is this year’s Skin Cancer Foundation Champions for Change Honoree. The Hacking Dermatology 2019 Hackathon puts innovation front and center.
News | October 4, 2019
The La Roche-Posay North American Foundation has opened a call for scientific abstracts. The La Roche-Posay North American Foundation was established in 2005 to support outstanding candidates with promising projects in the field of...
DermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates
DermWireTV: Cosmetic Surgery Forum Highlights, LEO Focuses on AD
Post-Market Price Changes Alone Account for Most Recent Spending Growth for Biologics, and Rebates Have Little Impact
Dermira Shares Positive Data From Phase 2b Study of Lebrikizumab for Atopic Dermatitis at Fall Clinical Dermatology Conference
Lilly: New Data for Treatment of Complex Dermatological Conditions at EADV, Maui Derm NP+PA